Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Association With Chemotherapy in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma.

Trial Profile

Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Association With Chemotherapy in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Zastumotide (Primary) ; Dacarbazine
  • Indications Malignant melanoma
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms MET-chemo
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 31 Mar 2015 Status changed from completed to discontinued as per ClinicalTrials.gov record.
    • 09 Nov 2014 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 16 May 2014 Planned end date changed from 1 Jun 2014 to 1 May 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top